(Click sector to view stock chart)
Drug Manufacturers Other
(Click stock symbol to view stock chart, Support, Resistance, Pivot, Option chain, Volume, P/E, High, Low, Close, Market Cap, Average Volume, Dividend, % Change, $ Change, R1, R2, S1, S2, Previous Close, RSI - MACD - Williams %R - Stochastics - PPO, CMF, ADX, Aroon and more.......)
ISIS PHARMACEUTICALS INC (ISIS)
Isis Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery and development of drugs to treat various therapeutic areas, including inflammatory, metabolic, and cardiovascular diseases, as well as cancer. The company operates through two segments, Drug Discovery and Development, and Ibis. The Drug Discovery and Development segment develops antisense inhibitors through its proprietary technology. The company markets its antisense drug, Vitravene, for the treatment of cytomegalovirus and retinitis in AIDS patients in the United States and Europe. It also develops new formulations of antisense drugs, such as oral, topical cream, subcutaneous, intravitreal, aerosol, and enema. The company's drugs under development include Alicaforsen for Ulcerative Colitis in Phase II clinical trial and ISIS 113715 for diabetes in Phase II clinical trial. In addition, it develops second-generation inhibitors, such as apoB-100 for the lowering of cholesterol and ISIS 301012, a Phase I study of an oral capsule formulation. The Ibis segment offers Triangulation Identification for Genetic Evaluation of Risks (TIGER) technology, a biosensor system, for identification of infectious diseases. TIGER biosensor system identifies various bacteria and viruses in both environmental and human clinical samples and used for epidemiological surveillance, biological products screening, and microbial forensics applications. The company has strategic alliance and collaboration agreements with Novartis Ophthalmics AG; Ercole Biotech, Inc.; Alnylam Pharmaceuticals, Inc.; OncoGenex Technologies, Inc.; Santaris Pharma A/S; Eli Lilly and Company; Antisense Therapeutics, Ltd.; and Sarissa, Inc. Isis Pharmaceuticals was founded in 1989 and is headquartered in Carlsbad, California.
ALEXION PHARMACEUTICALS INC (ALXN)
Alexion Pharmaceuticals, Inc., together with its subsidiaries, engages in the discovery and development of biologic therapeutic products for the treatment of severe diseases. It develops therapeutic products for the treatment of hematologic and cardiovascular disorders, autoimmune diseases, and cancer; and additional antibody therapeutics for other medical needs. The company primarily develops two lead product candidates, eculizumab and pexelizumab, which address specific diseases that arise when the human immune system produces inflammation in the human body. Eculizumab is in phase III clinical development for treatment of Paroxysmal Nocturnal Hemoglobinuria, a chronic hematologic disease. Pexelizumab is in clinical development for the reduction of the incidence of death, myocardial infarction or heart attack, and other complications associated with coronary artery bypass graft surgery; and for acute myocardial infarction. Alexion Pharmaceuticals has a strategic alliance with Procter and Gamble Pharmaceuticals for the development of pexelizumab. The company was co-founded by Leonard Bell, Stephen P. Squinto, Scott A. Rollins, and Joseph A. Madri in 1992. Alexion Pharmaceuticals is headquartered in Cheshire, Connecticut.
MGI Pharma, INC., a biopharmaceutical company, engages in the acquisition, development, and commercialization of proprietary pharmaceutical products for the needs of cancer patients. The company's product portfolio includes, Aloxi (palonosetron hydrochloride) injection for the prevention of chemotherapy-induced nausea and vomiting; Salagen tablets (pilocarpine hydrochloride) for the symptoms of radiation-induced dry mouth in head and neck cancer patients, as well as to rheumatologists as a treatment for dry mouth associated with the autoimmune disease Sjögren's syndrome; Hexalen (altretamine) capsules, which is an orally administered chemotherapeutic agent for ovarian cancer patients; and Kadian (morphine sulfate sustained release) capsules for moderate to severe pain associated with cancer. The company's products in various phases of clinical trials include Dacogen (decitabine) injection for the treatment of patients with myelodysplastic syndrome; Saforis oral suspension for chemotherapy induced inflammation of the tissues lining the mouth, or oral mucositis; ZYC101a for young women with cervical dysplasia; Irofulven for the treatment of prostate, liver, ovarian, and pancreatic tumors; and other acylfulvene analogs. MGI PHARMA markets its products through direct sales force within the United States and through alliances with other pharmaceutical or biotechnology companies in other countries. MGI PHARMA has alliances with Helsinn Healthcare SA; Kissei Pharmaceutical Co., Ltd.; Dainippon Pharmaceutical Co., Ltd.; Pfizer, Inc.; and Novartis Pharma AG. The company was incorporated in 1979 as Molecular Genetics, Inc. and changed its name to MGI PHARMA, Inc. in 1990. MGI PHARMA is headquartered in Bloomington, Minnesota.
Chattem, Inc. engages in the marketing and manufacture of a portfolio of branded over-the-counter (OTC) healthcare products, toiletries, and dietary supplements. Its products include topical analgesics, medicated skin care products, medicated dandruff shampoos and conditioner, dietary supplements, and other OTC and toiletry products. The company's topical analgesics comprise arthritis pain reliever, such as ICY HOT and ASPERCREME. Its medicated skin care products consist of GOLD BOND medicated skin care powder, cream, lotion, first aid, and foot care products; and PHISODERM medicated acne treatment products and skin cleansers. The company's medicated dandruff shampoos and conditioner are marketed under the brand name, SELSUN BLUE. Chattem's dietary supplements include DEXATRIM, GARLIQUE, and NEW PHASE. Its other OTC and toiletry products comprise PAMPRIN, a menstrual analgesic; HERPECIN-L, a lip care product; BENZODENT, a dental analgesic cream; and toiletries, such as BULLFROG, a line of sun blocks; ULTRASWIM, a chlorine-removing shampoo; and SUN-IN, a hair lightener. Chattem's products are sold primarily through mass merchandisers, independent and chain drug stores, drug wholesalers, and food stores in the United States and in various markets in approximately 80 countries throughout the world. The company was founded by Zeboim Cartter Patten as the Chattanooga Medicine Company in 1879. It changed its name to Chattem Drug and Chemical Company in 1945 and to Chattem, Inc. in 1978. The company is headquartered in Chattanooga, Tennessee.
ArQule, Inc., a biotechnology company, engages in the research and development of small-molecule cancer therapeutics based on its Activated Checkpoint Therapy (ACT) platform. The ACT platform is designed to produce small molecule compounds that selectively kill cancer cells while leaving normal cells unharmed. Its primary product consists of ARQ 501, a Phase I oncology product for cancer patients with solid tumors. The company also has products in preclinical and research stages. ArQule was founded in 1993 and is headquartered in Woburn, Massachusetts.
Novo Nordisk A/S, a healthcare company, engages in the discovery, development, manufacture, and marketing of pharmaceutical products and services. The company operates in two segments, Diabetes Care and Biopharmaceuticals. The Diabetes Care segment comprises insulin franchise, including insulin analogues, human insulin and insulin-related sales, and oral antidiabetic drugs. The Biopharmaceutical segment includes therapy areas, such as hemostasis management, growth hormone therapy and hormone replacement therapy, and other products. Novo Nordisk distributes its products primarily through distributors and independent agents. The company markets its products primarily in North America, Japan, and Europe. Novo Nordisk has a collaboration agreement with Aurigene Discoveries Technologies, which encompasses a joint discovery effort by both the companies on a target covering the discovery and preclinical development of lead series at Aurigene. The company was founded in 1925 and is headquartered in Bagsvaerd, Denmark.
Gentium S.p.A., a biopharmaceutical company, engages in the research, development, and manufacture of drugs to treat and prevent various vascular diseases and conditions related to cancer and cancer treatments. It manufactures defibrotide to treat deep vein thrombosis, and to treat and prevent various vascular diseases with risk of thrombosis. The company also conducts Phase III clinical trials of defibrotide to treat Veno-Occlusive Disease with multiple-organ failure; and phase I/II clinical trials to treat multiple myeloma. In addition, Gentium offers urokinase, which is used to treat various vascular disorders, such as deep vein thrombosis and pulmonary embolisms; and heparin calcium, which is used for the treatment of certain types of lung, blood vessel, and heart disorders, and administration during or after certain types of surgery, such as open heart and bypass surgeries. Further, it manufactures sulglicotide, which is intended to treat peptic ulcers. Additionally, Gentium develops a formulation of the drug mesalazine to treat inflammatory bowel disease. It sells its products primarily in Italy. The company was founded in 1993 as Pharma Research S.r.L. and changed its name to Gentium S.p.A. in 2001. Gentium is based in Villa Guardia, Italy.
NexMed, Inc., a pharmaceutical and medical technology company, engages in the design, development, manufacture, and commercialization of therapeutic products based on proprietary delivery systems. It develops transdermal treatments based on the NexACT drug delivery technology, which might enable an active drug to be better absorbed through the skin. The NexACT transdermal drug delivery technology is designed for the absorption of an active drug through the skin and enabling high concentrations of the active drug to penetrate the desired site of the skin or extremity. The company's primary NexACT product under development is the Alprox-TD cream treatment for erectile dysfunction. NexMed also develops Femprox an alprostadil-based cream product intended for the treatment of female sexual arousal disorder; NM100060 nail lacquer topical solution; NM100061 early ejaculation cream; NM100064 arthritic pain patch; NM100065 anti-emetic patch; and NM100080 wound healing/decubitus ulcers cream. The company operates in the United States and Hong Kong. NexMed was incorporated in 1987 and is based in Robbinsville, New Jersey.
Axcan Pharma, Inc. engages in the research, development, marketing, and sale of pharmaceutical products for the treatment of gastrointestinal diseases and disorders. Its products include ULTRASE, PANZYTRAT, and VIOKASE for the treatment of gastrointestinal symptoms related to cystic fibrosis; URSO/URSO 250, URSO FORTE/URSO DS, and DELURSAN for the treatment of cholestatic liver diseases; SALOFALK and CANASA for the treatment of inflammatory bowel diseases; and CARAFATE/SULCRATE for the treatment of gastric duodenal ulcers. The company also develops various pharmaceutical projects, including ITAX for the treatment of functional dyspepsia. Axcan Pharma sells its products primarily to hospitals, wholesale drug companies, and distributors in North America and Europe. It has an exclusive license from Abbott Laboratories to develop, manufacture, and market Itopride in North America, the European Union, and Latin America. The company was founded in 1982 by Leon F. Gosselin. It was formerly known as 115391 Canada, Inc. and changed its name to Interfalk Canada, Inc. in 1983. Further, Interfalk Canada changed its name to Axcan Pharma, Inc. in 1994. Axcan Pharma is headquartered in Mont Saint-Hilaire, Canada.
PHARMION CORPORATION (PHRM)
Pharmion Corporation primarily engages in the acquisition, development, and commercialization of pharmaceutical products for the treatment of oncology and hematology patients. The company's product acquisition and licensing efforts are focused on both late-stage development products, as well as those approved for marketing. Its product portfolio includes Thalidomide Pharmion and Thalidomide Laphal for the treatment of relapsed and refractory multiple myeloma; Vidaza, used for the treatment of myelodysplastic syndromes; Innohep, for the treatment of deep vein thrombosis; and Refludan, which is used for the treatment of heparin-induced thrombocytopenia. The company primarily operates in the United States, Europe, and Australia. Pharmion Corp. has a co-development and license agreement with GPC Biotech AG for satraplatin, the oral platinum-based compound in advanced clinical development. The company was founded in 1999 and is headquartered in Boulder, Colorado.
KENDLE INTERNATIONAL INC (KNDL)
Kendle International Inc., a contract research organization, provides integrated clinical research services worldwide. The company's services comprise clinical trial management, clinical data management, statistical analysis, medical writing, regulatory consultation, and organizational meeting management and publication services on a contract basis to the pharmaceutical and biotechnology industries. It performs drug development process through various information technology platforms, such as proprietary TrialWare software, including TrialWeb. The company provides contract services related to Phase I through IV clinical trials. It primarily operates in North America, Latin America, Europe, Asia, Africa, and Australia. Kendle International was founded by Candace Kendle and Chris Bergen in 1981, and is headquartered in Cincinnati, Ohio.
WARNER CHILCOTT LIMITED (WCRX)
Warner Chilcott Limited, a specialty pharmaceutical company, engages in the development, manufacture, marketing, and sale of branded prescription pharmaceutical products in women's healthcare and dermatology primarily in the United States. It offers various women healthcare products, including LOESTRIN 24 FE, OVCON 50, and FEMCON FE to prevent pregnancy; ESTROSTEP FE to prevent pregnancy and treat moderate acne in women, who desire oral contraception; FEMHRT 1/5 and .5/2.5 Oral to treat moderate to severe vasomotor symptoms and urogenital symptoms associated with menopause; and ESTRACE cream to treat vaginal and vulvar atrophy. The company also offers various dermatology products, such as TACLONEX and DOVONEX for the topical treatment of psoriasis; and DORYX, an oral adjunctive therapy for severe acne. In addition, its products under development include WC2061, an oral contraceptive, which is in a phase II pilot study; WC3016, an oral contraceptive that is in Phase III development stage; WC3026, an oral contraceptive which has completed Phase II stage; GD1105, a contraceptive vaginal ring that is in the preclinical phase; WC3018, which is in the preclinical phase for the treatment of acne and other inflammatory skin conditions; TD1414, a topical antibiotic for skin infections that is in late preclinical phase; WC2063, which is in the preclinical stage of development; LEO 80-185 that has completed Phase III to treat psoriasis of the scalp and body; LEO 80-190, which has completed Phase II stage for the topical treatment for psoriasis; and WC3027 that is in the preclinical phase for the treatment of inflammatory skin conditions. Its principal customers include wholesale pharmaceutical distributors, and major retail drug and grocery store chains. Warner Chilcott has license and supply agreement with LEO Pharma A/S. The company was founded in 1968 and is headquartered in Rockaway, New Jersey.
Pain Therapeutics, Inc., a development stage company, engages in the development of drugs for use in pain management, principally in the area of opioid painkillers. The company's clinical pipeline comprises three proprietary drug candidates, which include Oxytrex, an oral opioid painkiller that is in two Phase III clinical trials for the treatment of severe chronic pain; PTI-901, which is in two Phase III clinical trials to treat men and women with irritable bowel syndrome; and Remoxy, an anti-abuse version of long-acting oxycodone that is in one Phase III clinical trial. It has research and collaboration agreement with Durect Corporation. Pain Therapeutics has a strategic alliance with King Pharmaceuticals, Inc. to develop and commercialize Remoxy and other abuse-resistant opioid painkillers. The company was founded in 1998 and is based in South San Francisco, California.
POLYMEDICA CORPORATION (PLMD)
PolyMedica Corporation provides healthcare products and related services, primarily to seniors in the United States. It operates through three segments: Liberty Diabetes, Liberty Respiratory, and Pharmaceuticals. The Liberty Diabetes segment sells diabetes testing supplies and related products to customers suffering from diabetes. The Liberty Respiratory segment sells prescription respiratory medications and supplies to customers suffering from chronic obstructive pulmonary disease and other breathing disorders. The Pharmaceuticals segment sells prescription medications directly to consumers, as well as manufactures and sells prescription urology and suppository, and over-the-counter female urinary discomfort products. Its prescription urology products include urinary analgesics, antispasmodics, local anesthetics, and analgesic suppositories. This segment markets and sells prescription medications primarily to customers of its Liberty Diabetes and Liberty Respiratory segments. The company sells its prescription urology products to drug distributors; and female urinary discomfort products and home medical diagnostic kits to a network of drug store chains, supermarkets, mass merchandisers, and drug distributors. PolyMedica was organized in 1988 and is headquartered in Woburn, Massachusetts.
Shire plc, a specialty pharmaceutical company, engages in the development and marketing of products in the areas of central nervous system, gastrointestinal, renal diseases, and human genetic therapies. The company's product portfolio includes ADDERALL and ADDERALL XR for attention deficit hyperactivity disorder; ADEPT for reduction of adhesions following abdominal surgery; AGRYLIN for the treatment of essential thrombocythaemia; CALCICHEW range used in the treatment and prevention of osteoporosis; CARBATROL, indicated for the treatment of epilepsy; DYNEPO for the treatment of anaemia in patients with chronic renal failure; EQUETRO used for the treatment of acute manic and mixed episodes associated with bipolar 1 disorder; and FOSRENOL, indicated to reduce serum phosphate in patients with end-stage renal disease. It also markets PENTASA for the treatment of patients with mild to moderately active ulcerative colitis; PROAMATINE for the treatment of symptomatic orthostatic hypotension; REMINYL XL for the symptomatic treatment of mild to moderately severe dementia of the Alzheimer type; REPLAGAL, which is indicated for long-term enzyme replacement therapy in patients with a confirmed diagnosis of Fabry Disease; SOLARAZE for the treatment of actinic keratosis; 3TC tablets for the treatment of HIV infection; VANIQA used to treat facial hirsutism in women; XAGRID used for the reduction of elevated platelet counts in at-risk essential thrombocythaemia patients; and ZEFFIX, indicated for the treatment of chronic hepatitis B infection. It markets its products through distributors in the United States, Canada, the United Kingdom, Ireland, Germany, France, Spain, Italy, and Singapore. Shire plc was founded by Dennis Stephens, Harry Stratford, Peter Moriarty, and Geoff Hall in 1986. The company was formerly known as Shire Pharmaceuticals Group plc and changed its name to Shire plc in November 2005. Shire plc is headquartered in Basingstoke, the United Kingdom.
DURECT CORPORATION (DRRX)
DURECT Corporation develops pharmaceutical systems based on its proprietary drug delivery technology platforms. It has various product candidates under development in the areas of pain, and other chronic diseases and disorders. Its primary product candidates in development include SABER-Bupivacaine, TRANSDUR-Sufentanil, ORADUR- Oxycodone, DURIN-Leuprolide, and CHRONOGESIC. SABER-Bupivacaine, a post-operative pain relief depot product candidate, is a sustained release injectible using DURECT's SABER delivery system to deliver bupivacaine. TRANSDUR-Sufentanil, a transdermal sufentanil product candidate in phase II clinical studies, uses the TRANSDUR delivery system to deliver sufentanil, an opioid medication, to provide chronic pain relief for up to seven days. ORADUR- Oxycodone, an oral opioid product in phase III clinical studies, would be used to decrease the potential for oxycodone abuse. DURIN-Leuprolide is a product candidate using the DURIN implant system to deliver the peptide leuprolide to treat Alzheimer's disease. The CHRONOGESIC Pain Therapy System is an osmotic implant that would deliver sufentanil for an extended duration. CHRONOGESIC would be used to treat chronic pain and is based on the DUROS System, an osmotic pump. DURECT also engages in the research and development pharmaceutical systems in various therapeutic areas, including chronic pain, central nervous system disorders, and cardiovascular disease. In addition, the company manufactures and sells osmotic pumps used for animal research, and various biodegradable polymers for pharmaceutical and medical device clients for use as raw materials in their products. DURECT has strategic partnerships with Pain Therapeutics, Inc.; Voyager Pharmaceutical Corporation; Endo Pharmaceuticals, Inc.; Endo Pharmaceuticals, Inc.; and NeuroSystec Corporation. The company was co-founded by Felix Theeuwes, James E. Brown, and Thomas A. Schreck in 1998. DURECT is headquartered in Cupertino, California.
Sciele Pharma, Inc., a pharmaceutical company, engages in the development, marketing, and sale of prescription products for cardiovascular/diabetes diseases and women's health. The company's products include Sular, an antihypertensive prescription medication; Fortamet, a type 2 diabetes prescription medication; Altoprev for the treatment of high cholesterol; Triglide, an oral treatment for lipid disorders, such as elevated triglycerides; and Nitrolingual spray for acute relief or prevention of chest pain associated with angina pectoris that results from coronary artery disease. It also offers Prenate Elite and OptiNate, a prescription multivitamin/multimineral nutritional supplement for improving the nutritional status of women throughout pregnancy and in the postnatal period; and Ponstel for the relief of pain for patients and for primary dysmenorrhea, which is pain associated with menstruation. In addition, Sciele Pharma offers Zovirax, used in the treatment of type I (cold sores) and type II (genital) herpes simplex viruses; Ostiva, which offers a nutritional foundation for maintaining bone health; Furadantin for the treatment of urinary tract infections; Cognex for the treatment of mild to moderate dementia associated with Alzheimer's disease; Robinul and Robinul Forte that belong to a class of drugs known as anticholinergics, which reduce the motion of the gastrointestinal tract and decrease stomach; Zoto-HC ear drops for the treatment of swimmer's ear infections; and Zebutal capsules for the treatment of tension headaches. The company sells its products to pharmaceutical wholesalers, chain drug stores, other retail merchandisers, and directly to pharmacies. Sciele Pharma was founded in 1992. It was formerly known as First Horizon Pharmaceutical Corporation and changed its name to Sciele Pharma, Inc. in 2006. The company is headquartered in Atlanta, Georgia.
TEVA PHARMACEUTICAL INDUSTRIES LIMITED (TEVA)
Teva Pharmaceutical Industries Limited, a pharmaceutical company, engages in the development, manufacture, and marketing of generic and human drugs worldwide. Its generic pharmaceutical products include tablets, capsules, ointments, creams, liquids, and injectables. The company's active pharmaceutical ingredients include peptide active pharmaceutical ingredients. It also develops technologies, such as fermentation processes. The company has strategic alliances with Biovail Corporation International, Savient Pharmaceuticals, Inc., Impax Laboratories, Inc., and Andrx Corporation. Teva Pharmaceutical Industries Limited was founded in 1901 and is headquartered in Petach Tikva, Israel.
UNITED THERAPEUTICS CORPORATION (UTHR)
United Therapeutics Corporation (UTC), a biotechnology company, engages in the development and commercialization of therapeutic products for patients with chronic and life-threatening cardiovascular, cancer, and infectious diseases. The company's primary product, Remodulin, an injection for the treatment of pulmonary arterial hypertension in patients with NYHA class II-IV symptoms to diminish symptoms associated with exercise. UTC also develops four therapeutic platforms: immunotherapeutic monoclonal antibodies, which are antibodies that activate patients' immune systems to treat cancer, including OvaRex, which would be used for the treatment of metastatic ovarian cancer; glycobiology antiviral agents that are small molecules and would be used as an oral therapy for hepatitis C and other infections; telemedicine, which includes sportable digital devices that enable physicians to remotely monitor patients' bodily measurements such as heart function, including the CardioPAL family of cardiac event recorders and the Decipher Holter monitors; and arginine formulations, including the HeartBar and other products, which deliver the amino acid arginine that is necessary for maintaining vascular function. The company was founded in 1996 as Lung Rx, Inc. and changed its name to United Therapeutics Corporation in 1997. UTC was founded by Martine Rothblatt. United Therapeutics Corporation is headquartered in Silver Spring, Maryland.
Allergan, Inc. engages in the development and commercialization of pharmaceutical products for the ophthalmic, neurological, dermatological, and other markets. It engages in pharmaceutical research related to disease areas, such as glaucoma, retinal disease, dry eye, psoriasis, acne, and movement disorders. The company also offers aesthetic-related pharmaceuticals and over-the-counter products. Allergan offers prescription and nonprescription products to treat diseases and disorders of the eye, including glaucoma, dry eye, inflammation, infection, and allergy. Its glaucoma treatment products include Alphagan and Alphagan P, a brimonidine tartrate ophthalmic solution; Lumigan, a bimatoprost ophthalmic solution; and Restasis, a cyclosporine ophthalmic emulsion. Its ophthalmic anti-inflammatory products include Acular and Acular LS, as well as Pred Forte, a topical steroid. The company's ophthalmic infection treatment products include Ocuflox, Oflox, Zymar, and Exocin. It offers Alocril and Elestat ophthalmic solutions for the treatment of itch associated with allergic conjunctivitis. The company's neuromodulator product, Botox, is used therapeutically in the treatment of neuromuscular disorders. Allergan's skin care products include Tazorac gel for the treatment of plaque psoriasis; Azelex cream used in the topical treatment of mild to moderate inflammatory acne; Avage, a tazarotene cream indicated for the treatment of facial fine wrinkling, mottled hypo and hyperpigmentation, and benign facial lentigines; Prevagetm, an antioxidant cream, that reduces the appearance of fine lines and wrinkles, as well as provides protection against sun damage, air pollution, and cigarette smoke; and glycolic acid-based products. Allegran, Inc. has a strategic research collaboration agreement with ExonHit Therapeutics to identify new molecular targets based on ExonHits' gene profiling DATAS technology. Allegran was incorporated in 1948 and is headquartered in Irvine, California.
SIGA TECHNOLOGIES INC (SIGA)
SIGA Technologies, Inc. engages in the discovery, development, and commercialization of vaccines, antibiotics, and novel anti-infectives for the prevention and treatment of infectious diseases. It applies bacterial and viral genomics in the design and development of its products. The company offers products for use in defense against biological warfare agents, such as Smallpox and Arenaviruses. It has developed two methods in the development of vaccines, bacterial commensal vectors, which enables rapid production of live recombinant vaccines against biological agents; and surface protein expression system, used in the production of foreign proteins for use in subunit vaccine formulations. The company is also developing antibiotics to hit the bacterial adhesion organelles, as well as a technology for the mucosal delivery of its vaccines, which would allow the vaccines to activate the immune system at the mucus lined surfaces of the body, including the mouth, the nose, the lungs, and the gastrointestinal and urogenital tracts. The company's anti-infective product portfolio includes gram-positive antibiotic technology, gram-negative antibiotic technology, and broad-spectrum antibiotic technology targeted principally towards drug-resistant bacteria and hospital-acquired infections. SIGA Technologies has license agreements and collaborative research arrangements with Rockefeller University, Oregon State University, National Institutes of Health, Washington University, Regents of the University of California, and TransTech Pharma, Inc. The company was founded in 1995 and is headquartered in New York City.
CARDIOME PHARMA CORPORATION (CRME)
Cardiome Pharma Corp. develops cardiovascular drugs with a focus on the treatment of atrial arrhythmias and congestive heart failure. It has one completed and two ongoing Phase III clinical trials in collaboration with Fujisawa Healthcare, Inc., its collaborative partner for RSD1235 (iv) for the acute treatment of atrial fibrillation and atrial flutter. The company's other development stage products comprise RSD1235, a chemical entity designed to treat atrial fibrillation; and Oxypurinol, an inhibitor of xanthine oxidase, for the treatment of congestive heart failure. In addition, Cardiome Pharma has licenses and collaborative research agreements with the University of British Columbia, The Johns Hopkins University, and Genzyme Corp. The company was incorporated in 1986 as Nortran Resources, Ltd. and changed its name to Nortran Pharmaceuticals, Inc. in 1992. Further, it changed its name to Cardiome Pharma Corp. in 2001. Cardiome Pharma is headquartered in Vancouver, Canada.
Geron Corporation, a biopharmaceutical company, engages in the development and commercialization of therapeutic and diagnostic products for cancer based on its telomerase technology, and cell-based therapeutics using its human embryonic stem cell (HESC) technology. The company develops anticancer therapies based on telomerase inhibitors, telomerase therapeutic vaccines, and, through its licensees, telomerase-based oncolytic (cancer-killing) viruses. It uses HESCs for the manufacture of replacement cells and tissues. It intends to use HESC technology to enable the development of transplantation therapies, facilitate pharmaceutical research and development practices, and for research in human developmental biology. Geron Corporation's nuclear transfer technology is a method for generating whole animals from genetic material derived solely from the nucleus of a single cell obtained from an individual animal. The company was incorporated in 1990 and is headquartered in Menlo Park, California.
Cephalon, Inc., a biopharmaceutical company, engages in the discovery, development, and marketing of products to treat sleep disorders, neurological disorders, cancer, and pain primarily in the United States. The company, through its wholly-owned subsidiary, CIMA LABS INC., also develops and manufactures orally disintegrating tablets using proprietary technologies. It markets three proprietary products, including Provigil for treating of excessive sleepiness associated with obstructive sleep apnea/hypopnea syndrome and shift work sleep disorder; Actiq for treating pain in opiod-tolerant cancer patients; and Gabitril, which is used as an adjunct therapy for treatment of partial seizures associated with epilepsy. The company sells its products primarily in North America and Europe. Cephalon has an agreement with Bio3 Research and Creabilis to develop K 252a-based products as topical therapies for psoriasis and for the treatment and prevention of restenosis. The company was founded by Frank Baldino, Jr. and is headquartered in West Chester, Pennsylvania.
ELITE PHARMACEUTICALS INC (ELI)
Elite Pharmaceuticals, Inc., a specialty pharmaceutical company, engages in the development and manufacture of oral, controlled release products. The company markets Lodrane 24 through ECR Pharmaceuticals and has six drug products under development in the therapeutic areas that cover therapeutic areas for pain, angina, hypertension, cardiovascular, allergy, and infection. Elite Pharmaceuticals has an agreement with Orit Laboratories, LLC to co-develop and commercialize an extended release drug product for treatment of anxiety. The company was formed in 1984 and is based in Northvale, New Jersey.
DR. REDDYS LABORATORIES LTD (RDY)
Dr. Reddy's Laboratories Limited engages in the development, manufacture, and marketing of pharmaceutical products. The company produces finished dosage forms, active pharmaceutical ingredients, diagnostic kits, critical care products, and biotechnology products. It also conducts research in the areas of cancer, diabetes, cardiovascular diseases, inflammation, and bacterial infection. Dr. Reddy's Laboratories sells its products in approximately 100 countries worldwide, including the United States, Russia and other European countries, India, and China. The company has strategic alliances with Par Pharmaceuticals, Inc.; Leiner Health Products, LLC; Cobalt Pharmaceuticals, Inc.; and Pharmascience, Inc. Dr Reddy's Laboratories has a co-development and commercialization agreement with Rheoscience A/S for the joint development and commercialization of balaglitazone (DRF 2593), a partial PPAR gamma agonist, for the treatment of type 2 diabetes. The company was founded by K. Anji Reddy in 1984. Dr. Reddy's Laboratories is headquartered in Hyderabad, India.
POZEN, Inc., a pharmaceutical company, develops therapeutic advancements for diseases with unmet medical needs. It focuses primarily on developing products for the treatment of migraine, acute, and chronic pain, as well as other pain-related indications. The company's lead product candidate is Trexima, which is being developed in collaboration with GlaxoSmithKline for the treatment of acute migraine. Trexima is GlaxoSmithKline's proposed brand name for a proprietary single tablet containing sumatriptan succinate, a 5-HT 1B/1D agonist formulated with RT Technology; and naproxen sodium, a non-steroidal anti-inflammatory drug (NSAID). The company is also developing product candidates that combine an acid inhibitor with an NSAID. POZEN has two product candidates in development that combine a proton pump inhibitor with an NSAID in a single tablet. They include PN 100, a combination of lansoprazole and naproxen; and PN 200, a combination of omeprazole and naproxen. These product candidates are intended to provide management of pain and inflammation associated with conditions, such as osteoarthritis, with fewer gastrointestinal complications compared to an NSAID taken alone. POZEN was founded in 1996 and is headquartered in Chapel Hill, North Carolina.
VERTEX PHARMACEUTICALS INCORPORATED (VRTX)
Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in the discovery, development, and commercialization of small molecule drugs for HIV infection, chronic hepatitis C virus infection, inflammatory and autoimmune disorders, cancer, pain, and bacterial infection. It offers Lexiva/Telzir and Agenerase for HIV infection. The company is developing Merimepodib and VX-950, which are in phase I and phase II stage; VX-765, VX-702, and Pralnacasan that are in phase II stage; VX-680, VX-944, and VX-322, which are in phase I and preclinical stage; and VX-409 and VX-692, that are in preclinical stage. Vertex Pharmaceuticals has collaboration agreements with Aventis S.A.; GlaxoSmithKline plc; Novartis Pharma AG; Merck & Co., Inc.; Mitsubishi Pharma Corp.; and Cystic Fibrosis Foundation Therapeutics Incorporated. It also has collaboration agreements with Schering AG; Kissei Pharmaceutical Co., Ltd.; and Eli Lilly and Company. In addition, it has a licensing agreement with Avalon Pharmaceuticals, Inc. for the development and commercialization of the IMPDH inhibitor VX-944 for the treatment of cancer. Vertex Pharmaceuticals was founded by Joshua Boger in 1989 and is headquartered in Cambridge, Massachusetts.
ADAMS RESPIRATORY THERAPEUTICS INC (ARXT)
Adams Respiratory Therapeutics, Inc., a specialty pharmaceutical company, focuses on the late-stage development, commercialization, and marketing of over-the-counter (OTC) and prescription pharmaceuticals for the treatment of respiratory disorders. The company markets six oral-solid OTC products for adults under Mucinex brand; six products in its Mucinex line of products for children; two Mucinex nasal spray products; and two products under its Delsym brand. It sells its products to drug wholesalers, retail drug stores, mass merchandisers, and grocery stores in the United States. Adams Respiratory Therapeutics has a license and collaboration agreement with MonoSol Rx, LLC to use MonoSol's proprietary rapidly dissolving thin-film drug delivery technology to develop and market respiratory products in North America. It also has a license and collaboration agreement with Lipocine, Inc. to develop prescription adult cough products. The company was founded in 1997 as Adams Laboratories, Inc. and changed its name to Adams Respiratory Therapeutics, Inc. in 2005. Adams Respiratory Therapeutics is headquartered in Chester, New Jersey.
CUBIST PHARMACEUTICALS INC (CBST)
Cubist Pharmaceuticals, Inc. engages in the research, development, and commercialization of products for anti-infective and acute care needs market. Its principal product, Cubicin, is approved in the United States for the treatment of skin and skin structure infections caused by certain gram-positive bacteria. The company's pipeline includes HepeX-B, a monoclonal antibody biologic that is in second of two Phase 2 trials, for the prevention of infection by Hepatitis B virus in liver transplant patients, as well as research efforts focused on members of the lipopeptide class of molecules. Cubist has a licensing agreement with XTL Biopharmaceuticals, Ltd., for the development and commercialization of HepeX-B. The company was founded in 1992 and is headquartered in Lexington, Massachusetts.
MILLENNIUM PHARMACEUTICALS INC (MLNM)
Millennium Pharmaceuticals, Inc. engages in the research, development, and commercialization of therapeutic products in the areas of cancer, cardiovascular, and inflammatory diseases. The company's products include VELCADE, a proteasome inhibitor for treating patients with multiple myeloma; and INTEGRILIN injection, a cardiovascular product. Its INTEGRILIN injection prevents aggregation of blood platelets and occlusion of the arteries supplying the heart muscle with oxygen to prevent the incidence of heart attack or death in patients with acute coronary syndrome, and for the treatment of patients undergoing percutaneous coronary intervention. The company's preclinical and clinical development drug candidates include MLN2704 for prostate cancer; MLN518 for acute myeloid leukemia; MLN8054 for solid tumor cancers; MLN2222 for reperfusion injury in patients undergoing cardiac surgeries; MLN1202 for rheumatoid arthritis multiple sclerosis; MLN3897 for chronic inflammatory diseases, such as rheumatoid arthritis; MLN02 for Crohn's disease; and MLN3701 for chronic inflammatory diseases, such as rheumatoid arthritis. It has strategic alliances with Ortho Biotech Products, L.P.; Schering-Plough, Ltd.; GlaxoSmithKline plc; Aventis Pharma; and Schering Corporation. Millennium Pharmaceuticals was founded in 1993 and is headquartered in Cambridge, Massachusetts.
RELIV INTERNATIONAL INC (RELV)
Reliv International, Inc., through its subsidiaries, engages in the development, manufacture, and marketing of proprietary nutritional products worldwide. The company's products include nutritional supplements, weight management products, functional foods, sports nutrition and a line of skin care products. Its nutritional supplements include vitamins, minerals, dietary supplements, herbs, and compounds. The functional foods are products designed to influence specific functions of the body. The company's products are distributed through a network marketing system. It offers an entrepreneurial opportunity for its distributors. Its distributors sell products directly to retail customers and sponsor other individuals as distributors. As of March 31, 2005, the company marketed its products through approximately 73,060 distributors worldwide. The company was founded in 1984 and is headquartered Chesterfield, Missouri.
INSPIRE PHARMACEUTICALS INC (ISPH)
Inspire Pharmaceuticals, Inc., a biopharmaceutical company, engages in discovery, development, and commercialization of prescription pharmaceutical products in the ophthalmic and respiratory therapeutic areas. It has product candidates in various stages of clinical development and various programs in preclinical development. The company's clinical product candidates are based on proprietary technology relating to P2 receptors. Its products in clinical development include INS365 Ophthalmic for treating dry eye disease and corneal wound healing; INS37217 Respiratory for the treatment of cystic fibrosis; INS37217 Ophthalmic for the treatment of retinal disease; and INS50589 Antiplatelet for use in acute cardiac care. In addition, the company has rights to co-promote Elestat, for the treatment of allergic conjunctivitis; and Restasis, for the treatment of dry eye disease in the United States under collaborative agreements with Allergan, Inc. It also has collaborative partnerships with Santen Pharmaceutical Co., Ltd., and Cystic Fibrosis Foundation Therapeutics, Inc., as well as license agreements with the University of North Carolina at Chapel Hill and Wisconsin Alumni Research Foundation. The company was incorporated in 1993 and is based in Durham, North Carolina.
ALLOS THERAPEUTICS INC (ALTH)
Allos Therapeutics, Inc., a biopharmaceutical company, engages in the development and commercialization of small molecule drugs for cancer treatments. Its three product candidates under development include Efaproxyn, PDX, and RH1. The Efaproxyn is a synthetic small molecule designed to sensitize hypoxic or oxygen-deprived areas of tumors during radiation therapy. It is evaluated as an adjunct to whole brain radiation therapy in a pivotal Phase 3 trial in women with brain metastases originating from breast cancer. PDX is a small molecule chemotherapeutic agent that inhibits dihydrofolate reductase, a folic acid dependent enzyme involved in the building of nucleic acid and other processes. PDX is in a Phase 1/2 single-agent study in patients with nonHodgkin's lymphoma; a Phase 1 combination study with docetaxel in patients with advanced cancer, including nonsmall cell lung cancer (NSCLC); and a Phase 1 single-agent study to determine the maximum tolerated dose of PDX in patients with NSCLC. RH1 is a small molecule chemotherapeutic agent that is bioactivated by the enzyme DT-diaphorase, which is over-expressed in various tumors relative to normal tissue, including lung, colon, breast, and liver tumors. The company was incorporated as HemoTech Sciences, Inc. in 1992 and changed its name to Allos Therapeutics, Inc. in 1994. Allos Therapeutics is headquartered in Westminster, Colorado.
BRADLEY PHARMACEUTICALS INC (BDY)
Bradley Pharmaceuticals, Inc. engages in the acquisition, development, and marketing of prescription and over-the-counter products. It operates through two segments, Doak Dermatologics, Inc. and Kenwood Therapeutics. The Doak Dermatologics segment promotes dermatologic and podiatric products, including its Carmol 40, Lidamantle, Rosula, and Zoderm product lines, to dermatologists and podiatrists in the United States. The Kenwood Therapeutics segment promotes gastrointestinal products, including Anamantle HC, Pamine, Pamine Forte, and Flora-Q to gastroenterologists, colon, and rectal surgeons. It also markets nutritional supplements and respiratory products. The company's products are manufactured by third parties and principally distributed through wholesalers to retail pharmacies and healthcare institutions throughout the United States and selected international markets. The company has a strategic relationship with Ventiv Health, Inc. Bradley Pharmaceuticals was founded by Daniel Glassman in 1985 and has principal executive offices in Fairfield, New Jersey.
ALEXZA PHARMACEUTICALS INC (ALXA)
Alexza Pharmaceuticals, Inc., a development stage company, focuses on the development and commercialization of products for the treatment of acute and intermittent conditions primarily in the United States. Its technology, the Staccato system, vaporizes unformulated drug to form a condensation aerosol that allows rapid systemic drug delivery through deep lung inhalation. The company has four product candidates in clinical development: AZ-001 (Staccato prochlorperazine) for the acute treatment of migraine headaches; AZ-002 (Staccato alprazolam) for the acute treatment of panic attacks associated with panic disorder; AZ-004 (Staccato loxapine) for the treatment of acute agitation in patients with schizophrenia; and AZ-003 (Staccato fentanyl) for the treatment of patients with acute pain. Its product candidate AZ-001 completed Phase IIb Clinical Trial; AZ-004 completed Phase IIa Clinical Trial; AZ-002 is in Phase IIa Clinical Trials; and AZ-003 completed a Phase I Clinical Trial. Alexza Pharmaceuticals has a development agreement with Autoliv ASP, Inc. for the development of heat packages that can be incorporated into proprietary single dose drug delivery device. The company, formerly known as FaxMed, Inc., was founded in 2000. FaxMed changed its name to Alexza Corporation in June 2001 and to Alexza Molecular Delivery Corporation in December 2001. Further, it changed its name to Alexza Pharmaceuticals, Inc. in July 2005. The company is based in Palo Alto, California.
AVI BioPharma, Inc., a biopharmaceutical company, engages in the development of therapeutic products based on NEUGENE antisense technology. Its principal products in development target life-threatening diseases, including cardiovascular disease, infectious disease, and cancer. AVI's lead product candidate, Resten-NG, is a NEUGENE antisense drug for treating cardiovascular restenosis, or the re-narrowing of a coronary artery following angioplasty. In addition to targeting specific genes in the body, AVI's antiviral program uses NEUGENE antisense compounds to combat disease by targeting singlestranded RNA viruses, including West Nile virus, hepatitis C virus, dengue virus, and Ebola virus. AVI has also evaluated Avicine, a therapeutic cancer vaccine, in six clinical trials involving colorectal and pancreatic cancer; completed Phase Ib/II trials of AVI-4557 targeting drug metabolism; and evaluated Phase I trials of AVI-4126 targeting polycystic kidney disease. The company has strategic alliances with SuperGen, Inc.; Medtronic, Inc.; and Exelixis, Inc. AVI was incorporated in 1980 as Antivirals, Inc. and changed its name to AVI BioPharma, Inc. in 1998. AVI is based in Portland, Oregon.
Alpharma, Inc., a global specialty pharmaceutical company, engages in the development, manufacture, and marketing of specialty generic human pharmaceutical and animal pharmaceutical products. The company offers a range of generic human pharmaceutical products in tablet, capsule, liquid, and topical formulations and dosage forms. It operates in five segments: Active Pharmaceutical Ingredients (API), Branded Pharmaceuticals (BP), International Generics (IG), U.S. Generic Pharmaceuticals (USG), and Animal Health (AH). The API segment offers a range of antibiotic fermentation based active pharmaceutical ingredients that are used in the manufacture of finished dose pharmaceutical products. The BP segment manufactures, develops, and markets a prescription pain medicine in a capsule dosage form under the trademark Kadian. It also markets a third party's branded prescription product in a tablet dosage form Pexeva. The IG segment offers a range of prescription pharmaceuticals that comprises antibiotic, analgesic/antirheumatic, psychotropic cardiovascular, cough and cold, and corticosteroid therapeutic products; and over-the-counter products that include skin care, gastrointestinal care, and pain relief products for human use. The USG segment provides generic prescription, specialty branded, and over-the-counter pharmaceuticals for human use. The AH segment offers medicated feed additives for food producing animals, such as poultry, cattle, and swine. It sells products primarily to wholesalers, distributors, hospitals, long-term care providers, managed care providers, and mail order companies, as well as merchandising chains in the United States, the United Kingdom, Germany, the Netherlands, Scandinavia, western Europe, Indonesia, China, Asia-pacific, and certain Middle Eastern countries. The company was formed as A.L. Laboratories, Inc. in 1975 and changed its name to Alpharma, Inc. in 1994. Alpharma is headquartered in Fort Lee, New Jersey.
SCICLONE PHARMACEUTICALS INC (SCLN)
SciClone Pharmaceuticals, Inc., a biopharmaceutical company, engages in the development and commercialization of therapeutics to treat life-threatening diseases. Its products include ZADAXIN is in phase 3 hepatitis C virus clinical trials, as well as in other late-stage clinical trials for the treatment of hepatitis B virus and certain cancers. The company also develops SCV-07, which is in preclinical studies, for the treatment of viral and other infectious diseases. The company sells its products primarily in Asia, the Middle East, and Latin America. SciClone Pharmaceuticals was founded in 1989 and is headquartered in San Mateo, California.
SuperGen, Inc., a pharmaceutical company, engages in the development and commercialization of the therapies for solid tumors, hematological malignancies, and blood disorders. The company offers Orathecin capsules, a second-generation topoisomerase I inhibitor, which causes single-strand breaks in the DNA of rapidly dividing tumor cells; Dacogen, a pyrimidine analog that decreases the amount of methylation at certain DNA sites; and Nipentis that is used for the treatment of hairy cell leukemia, a type of B-lymphocytic leukemia, as well as shows activity in various autoimmune diseases, including GvHD, bone marrow transplantation and multiple sclerosis. It also offers Mitomycin, Paclitaxel, Mitozytrex, Inhaled Orathecin, Partaject Orathecin, CZ 112, and Cremophor-free paclitaxel for solid tumors; Daunorubicin for Acute leukemias; Surface Safe for surface decontaminate; Partaject busulfan for Neoplastic meningitis/bone marrow transplant; Avicine for Therapeutic Vaccine; and VEGF for anti-angiogenesis. The company sells its products to cancer hospitals, clinics, private practice oncology clinics, oncology distributors, and drug wholesalers in the United States. SuperGen was founded in 1991 and is headquartered in Dublin, California.
Depomed, Inc., a development stage company, develops pharmaceutical products based on its proprietary oral drug delivery technologies. Its primary oral drug delivery system, Gastric Retention (GR) System offers orally administered and conveniently dosed drug therapy that provides continuous and controlled delivery of a drug over a multihour period. The company's products principally comprise Glumetza for the treatment of Type II diabetes; Proquin for treatment of urinary tract infections; and Gabapentin GR for adjunctive therapy for epileptic seizures and postherpetic pain. Its products under development include Furosemide GR for the treatment of severe congestive heart failure patients. Depomed, through collaboration agreements, also develops other product candidates for the delivery of large molecules, such as antisense compounds from the GR System; and a combination product comprising its Glumetza for Type II diabetes. It has collaboration agreements with Biovail Laboratories Incorporated; LG Life Sciences, Ltd.; New River Pharmaceuticals, Inc.; and AVI BioPharma, Inc. The company was founded by John W. Shell. Depomed was incorporated in 1995 and is based in Menlo Park, California.
PRANA BIOTECHNOLOGY LTD (PRAN)
Prana Biotechnology Limited, a development stage company, engages in the research and development of therapeutic drugs, which are designed to treat the underlying causes of degeneration of the brain and the eye as the aging process progresses. The company primarily focuses on Alzheimer's disease, age-related cataracts, Creutzfeldt-Jakob disease, Motor Neuron disease, and Parkinson's disease. Its development stage products include PBT-1 and PBT-2, which will be used for the treatment of Alzheimer disease. The company was co-founded by Geoffrey Paul Kempler. Prana Biotechnology was incorporated in 1997 and is based in Parkville, Australia.
ANGIOTECH PHARMACEUTICALS INC (ANPI)
Angiotech Pharmaceuticals, Inc. focuses on combining pharmaceutical compounds with medical devices and biomaterials to address common complications associated with certain surgical procedures and processes of various diseases worldwide. It primarily sells coronary stent systems incorporating the drug paclitaxel for the treatment of coronary artery disease. The company's other commercial products include VITAGEL surgical hemostat, a bioresorbable hemostatic material used to reduce patient blood loss during surgical procedures; CoSeal surgical sealant, a biomaterial surgical sealant used to enable tissue repair and regeneration; Collagraft and NeuGraft, collagen-based biomaterial products for orthopaedic and spinal surgery applications; and various polymeric biocompatible coatings for medical devices. Angiotech's ongoing clinical programs include TAXUS Liberte, Vascular Wrap, Adhibit, and Peripheral Drug Eluting Stent Program. TAXUS Liberte is a paclitaxel eluting coronary stent system to treat restenosis, and other local inflammatory and proliferative diseases. Vascular Wrap is used to prevent stenosis following vascular bypass surgery in the limbs. Adhibit adhesion prevention gel, a nondrug-loaded biomaterial product, is undergoing human clinical studies in Europe. Peripheral Drug Eluting Stent Program is a study of a paclitaxel-eluting stent to treat peripheral artery disease in the limbs. In addition, the company has other preclinical programs, including anti-infective central venous catheter program and intra-articular paclitaxel program for the prevention of post injury contractures and cartilage preservation. Angiotech has a strategic alliance with Baxter Healthcare Corporation and CombinatoRx. Angiotech was incorporated in 1989. The company was formerly known as Holwest Industries, Ltd. It changed its name to Angiogenesis Technologies, Inc. in 1992 and to Angiotech Pharmaceuticals, Inc. in 1996. The company is headquartered in Vancouver, Canada.
ENDO PHARMACEUTICALS HOLDINGS INC (ENDP)
Endo Pharmaceuticals Holdings, Inc. operates as a specialty pharmaceutical company in the United States. Through its wholly owned subsidiary, Endo Pharmaceuticals, Inc., it engages in the research, development, marketing, and sale of branded and generic pharmaceutical products primarily used to treat and manage pain. The company's branded products include Lidoderm, Percocet, Percodan, Frova, DepoDur, and Zydone. Lidoderm is a topical patch product containing lidocaine for the relief of the pain from post-herpetic neuralgia. Percocet and Percodan are used for the treatment of moderate-to-severe pain. Frova used for prevention of menstrually related migraine. DepoDur used for the treatment of pain following major surgery. Zydone tablets are also used for the relief of moderate-to-severe pain and contain hydrocodone/acetaminophen. The company's generic products comprise morphine sulfate, generic oxycodone hydrochloride, and acetaminophen product, which focus on pain management. Endo Pharmaceuticals also offers carbidopa/levodopa, the generic version of Sinemet for the treatment of the symptoms of idiopathic Parkinson's disease. In addition, the company is developing products for the acute, chronic, and neuropathic pain conditions, as well as in complementary therapeutic areas. It sells its products to pharmacy chains and wholesale drug distributors who supply to pharmacies, hospitals, governmental agencies, and physicians. The company has a strategic alliance with SkyePharma, Inc. Endo was incorporated in 1997 and is headquartered in Chadds Ford, Pennsylvania.
VALEANT PHARMACEUTICALS INTERNATIONAL (VRX)
Valeant Pharmaceuticals International (VPI), a research-based pharmaceutical company, engages in the discovery, development, manufacture, and marketing of various pharmaceutical products worldwide. Its products encompass various therapeutic areas, with a primary focus upon infectious disease, neurology, and dermatology. The company's research and new product development initiatives focus on treatments for hepatitis C, hepatitis B, HIV/AIDS, and cancer. VPI also develops, manufactures, and distributes prescription and nonprescription pharmaceuticals. Its prescription pharmaceutical products treat neuromuscular disorders, cancer, cardiovascular disease, diabetes, and psychiatric disorders. As of December 31, 2004, VPI's product portfolio comprised of approximately 575 branded products with approximately 2,400 stock-keeping units. The company markets its products through marketing and sales force, as well as sells directly to physicians, hospitals, wholesalers, and large drug store chains primarily in North America, Latin America, Europe, Asia, Africa, and Australia. VPI was incorporated as ICN Pharmaceuticals, Inc. in 1994 and changed its name to Valeant Pharmaceuticals International in 2003. The company is headquartered in Costa Mesa, California. Valeant Pharmaceuticals International acquired Xcel Pharmaceuticals, Inc. on March 2005.
The Medicines Company, a pharmaceutical company, engages in the acquisition, development, and commercialization of acute care hospital products. The company offers Angiomax, a direct thrombin inhibitor, for use as an anticoagulant in patients with unstable angina undergoing coronary angioplasty. It also develops clevelox, an intravenous drug intended for the short-term control of blood pressure in surgical patients, including patients undergoing cardiac surgery; and cangrelor, an antiplatelet agent that prevents platelet aggregation. The company markets, distributes, and sells its products to hospital management, physicians, hospital pharmacists, nurses, and other care staff in the United States, as well as through third-party distributors internationally. It has licensing agreements with Biogen Idec, Inc. and AstraZeneca AB. The company was founded in 1996 and is headquartered in Parsippany, New Jersey.
MARSHALL EDWARDS INC (MSHL)
Marshall Edwards, Inc. engages in the development and commercialization of drugs for the treatment of cancer. The company engages in the clinical development of a drug called Phenoxodiol for early stage prostate cancer, late stage hormone refractory prostate cancer, early stage cervical and vaginal cancer, chemo resistant and chemo refractory ovarian cancer, and renal cancer. Phenoxodiol induces cancer cell death through inhibition of anti apoptotic proteins, including XIAP and FLIPshort. It would increase the potency of signal transduction inhibitors by targeting multiple signaling pathways vital to the survival of most human cancer cells. Phenoxodiol is in the phase II trials in the U.S. and Australia. The company was incorporated in 2000 and is based in North Ryde, Australia. Marshall Edwards, Inc. is 86.9% owned by Novogen Limited, as of June 30, 2004.
DYNAVAX TECHNOLOGIES CORPORATION (DVAX)
Dynavax Technologies Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of products to treat and prevent allergies, infectious diseases, and chronic inflammatory diseases. The company's clinical development programs are based on immunostimulatory sequences, which are short DNA sequences that enable the immune system to fight disease and control chronic inflammation. Its pipeline includes TOLAMBA, a ragweed allergy immunotherapeutic, which is in a Phase II/III clinical trial and in a supportive clinical trial in ragweed allergic children; HEPLISAV, a hepatitis B vaccine in a pivotal Phase III clinical trial; a cancer therapy in a Phase II clinical trial; and an asthma immunotherapeutic that has shown preliminary safety and pharmacology in a Phase IIa clinical trial. The company was founded in August 1996 as Double Helix Corporation and changed its name to Dynavax Technologies Corporation in September 1996. Dynavax is based in Berkeley, California.
Lannett Company, Inc. engages in the development, manufacture, packaging, marketing, and distribution of pharmaceutical products in the United States. Its products portfolio comprises Acetazolamide for glaucoma; Butalbital, Aspirin, and Caffeine capsules to treat migraine headache; Ciprofloxacin tablets, an antibiotic; Digoxin tablets used to treat congestive heart failure in patients of various ages and demographic backgrounds; Dicyclomine tablets/capsules for irritable bowels; Diphenoxylate with atropine sulfate tablets to treat diarrhea; Hydromorphone HCL tablets to treat pain management; Levothyroxine Sodium and Unithroid tablets to treat hypothyroidism and other thyroid disorders; Methocarbamol tablets for muscle relaxer; Methyltestoterone/Esterified Estrogens tablets for hormone replacement; Phentermine HCL tablets to treat weight loss; Phenylpropanolamine tablets-vet for incontinence; Primidone tablets to treat convulsion and seizures in epileptic patients of all ages and demographic backgrounds; Terbutaline Sulfate tablets for the prevention and reversal of bronchospasm in patients 12 years of age and older with asthma and reversible bronchospasm associated with bronchitis and emphysema; and Unithroid tablets to treat thyroid deficiency. The company sells its pharmaceutical products to generic pharmaceutical distributors, drug wholesalers, chain drug retailers, private label distributors, mail-order pharmacies, other pharmaceutical manufacturers, managed care organizations, hospital buying groups, and health maintenance organizations. Lannett Company was founded in 1942 and is headquartered in Philadelphia, Pennsylvania.
YM BioSciences, Inc., a development stage biopharmaceutical company, engages in the research and development of products primarily for the treatment of cancer. Its product candidates in the clinical stage of development include Tesmilifene, Nimotuzumab, AeroLEF, Norelin, and Radiotheracim. Tesmilifene, which is in phase III clinical trial, is a small molecule chemopotentiator for the treatment of metastatic and recurrent breast cancer. Nimotuzumab, which is in phase II clinical trial, is an antiepidermal growth factor humanized monoclonal antibody for the treatment of epithelial cancers. AeroLEF, which is in phase II clinical trials, is a proprietary formulation of both free and liposome-encapsulated fentanyl administered by pulmonary inhalation, is being developed for the treatment of severe and moderate acute pain and cancer pain. Norelin is a phase II clinical trial product for the treatment of sex-hormone dependent cancers. Radiotheracim is a radiolabelled humanized monoclonal antibody, targeting the epidermal growth factor receptor, and is being developed for the treatment of brain cancers. The company also has a portfolio of preclinical compounds shown to act as chemopotentiators while protecting normal cells. YM BioSciences has a collaborative agreement with Sanofi-Aventis to investigate the effect of combining tesmilifene and docetaxel for the treatment of women with rapidly progressing metastatic breast cancer. The company was founded in 1994 and is headquartered in Mississauga, Canada.
SOMAXON PHARMACEUTICALS INC (SOMX)
Somaxon Pharmaceuticals, Inc., a specialty pharmaceutical company, engages in the in-licensing, development, and commercialization of product candidates for the treatment of diseases and disorders in the fields of psychiatry and neurology in the United States. The company's lead product includes SILENOR, for the treatment of insomnia that has completed Phase III clinical program. Its other products include Nalmefene, which would be used for smoking cessation and is in Phase II clinical trials; and for the treatment of pathological gambling and is in Phase II/III clinical trials. The company is also developing a new formulation of Acamprosate Calcium for the treatment of certain movement disorders. Somaxon Pharmaceuticals, Inc. was founded in 2003 and is headquartered in San Diego, California.
ADOLOR CORPORATION (ADLR)
Adolor Corporation, a development stage biopharmaceutical corporation, engages in the discovery, development, and commercialization of prescription pain management products primarily in the United States. Its lead product candidate, Entereg, is a small molecule, peripherally-acting mu opioid receptor antagonist. As of July 6, 2005, the company was under development of Entereg for the management of the gastrointestinal side effects associated with opioid use. Adolor other products under development include a sterile lidocaine patch, is in Phase 2 clinical development, for treating postoperative incisional pain, and analgesics for treating moderate-to-severe pain conditions. The company has collaboration agreement with Glaxo Group Limited for the development and commercialization of Entereg in multiple indications. It also has a license agreement with EpiCept Corporation to develop and commercialize a sterile lidocaine patch in North America. Adolor was formed in 1993 and is headquartered in Exton, Pennsylvania.
COLLAGENEX PHARMACEUTICALS INC (CGPI)
CollaGenex Pharmaceuticals, Inc. and its subsidiaries (CPI) operate as a specialty pharmaceutical company. It focuses on developing and marketing proprietary medical therapies to the dental and dermatology markets. The company's primary product, Periostat, is an orally administered, prescription dental pharmaceutical product to treat adult periodontitis. CollaGenex markets proprietary dental products of Atrix Laboratories, Inc. These products include Atridox, Atrisorb FreeFlow, and Atrisorb-D. Atridox is a locally-applied and antimicrobial therapy for the treatment of chronic adult periodontitis. Atrisorb FreeFlow is used in the surgical treatment of periodontal defects to help regenerate tissue. Atrisorb-D reduces the incidence of infections during guided tissue regeneration procedures. The company also markets Pandel, a prescription midpotency topical corticosteroid product licensed from Altana, Inc. In addition, it develops a pipeline of products, which are in clinical and preclinical development. These products are based on its proprietary platform technologies, IMPACs and Restoraderm. CPI distributes Periostat and Pandel through drug wholesalers in the United States. The company distributes the Atrix dental products through a specialty distributor who sells these products directly to dental practitioners in the United States and Puerto Rico. CollaGenex was founded in 1992 as CollaGenex, Inc. and changed its name to CollaGenex Pharmaceuticals, Inc. in 1996. The company is based in Newtown, Pennsylvania.
FOREST LABORATORIES INC (FRX)
Forest Laboratories, Inc. engages in the development, manufacture, and sale of both branded and generic forms of ethical drug products, as well as nonprescription pharmaceutical products sold over-the-counter. The company's products include Lexapro, Celexa, Namenda, Tiazac, Benicar, Benicar HCT, Milnacipran, CCR1, Lercanidipine, Campral, and Combunox. The Lexapro and Celexa are used for the initial and maintenance treatment of depressive disorders, and for generalized anxiety disorders. The Namenda, an N-methyl-D-aspartate-receptor antagonist, is used for the treatment of moderate to severe Alzheimer's disease. The Tiazac, Benicar, Benicar HCT, and Lercanidipine are used for hypertension. The Milnacipran is in Phase III development for the treatment of fibromyalgia syndrome. The CCR1 is a chemokine receptor involved in the inflammation process. Campral is used for the maintenance of abstinence from alcohol in patients with alcohol dependence. Combunox, an opioid and NSAID combination, is used for the short-term management of pain. It also has various products under development, which include RGH-188 in Phase I clinical trials, an atypical antipsychotic for the treatment of schizophrenia, bipolar mania, and other psychiatric conditions; phase I completed GRC 3886, a novel, orally available Phosphodiesterase-IV inhibitor in development for chronic obstructive pulmonary disorder and asthma; and Desmoteplase, a novel plasminogen activator, or blood clot-dissolving agent. The company markets its products directly and though independent distributors worldwide to physicians, pharmacies, hospitals, managed care, and other healthcare organizations. The company has strategic alliances with H. Lundbeck A/S; Merz Pharma GmbH; Sankyo Pharma; Merck Sante s.a.s.; Gedeon Richter Ltd.; Glenmark Pharmaceuticals; PAION GmbH; ChemoCentryx, Inc.; Cypress Bioscience, Inc.; and Recordati, S.p.A. Forest Laboratories was organized in 1956 and is based in New York City.
REGENERX BIOPHARMACEUTICALS INC (RGN)
RegeneRx Biopharmaceuticals, Inc. engages in the research and development of pharmaceutical products for the treatment of diseases that arise as a result of immune system disorders, including chronic viral infections, cancer, and autoimmune disease. It primarily develops Thymosin beta 4 (TB4) as a platform technology for the treatment of acute and chronic wounds, and for the treatment of various human diseases involving tissue and organ repair. The company has completed a Phase I human clinical trial with Thymosin beta 4. RegeneRx has a strategic alliance with Defiante Farmaceutica, L.d.a. to develop TB4 in Europe and certain other countries for the treatment of internal and external wound healing. The company was founded by Allan L. Goldstein in 1982 and is headquartered in Bethesda, Maryland.
ARENA PHARMACEUTICALS INC (ARNA)
Arena Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of drugs in the therapeutic areas of metabolic, cardiovascular, inflammatory, and central nervous system diseases. The company is developing a pipeline of compounds that act on drug targets called G protein-coupled receptors, using its proprietary technologies, including Constitutively Activated Receptor Technology and Melanophore. Arena's products principally include APD356, a Phase II clinical trial 5-HT2C serotonin receptor agonist, which would be used for the treatment of obesity; and APD125, a Phase I clinical trial product, for the treatment of insomnia. Arena Pharmaceuticals has research collaborations with Ortho-McNeil Pharmaceutical, Inc. and Merck & Co., Inc. for products in various indications. The company was co-founded by Dominic P. Behan and Jack Lief. Arena Pharmaceuticals was incorporated in 1997 and is based in San Diego, California.
TAPESTRY PHARMACEUTICALS INC (TPPH)
Tapestry Pharmaceuticals, Inc. focuses on the development of proprietary therapies for the treatment of cancer. The company's preclinical development stage products include Quassinoids and Peptide Linked Cytotoxics, which would be used for the treatment of cancers; and Oligo Therapy for Huntington's disease. Its Phase I clinical trial product includes TPI 287, which would be used for the treatment of prostate, nonsmall cell lung, pancreatic, ovarian, and colon cancer. The company was co-founded by Patricia A. Pilia. Tapestry Pharmaceuticals was incorporated in 1991 and is based in Boulder, Colorado.
NitroMed, Inc., a pharmaceutical company, engages in the research, development, and commercialization of pharmaceuticals based on the therapeutic benefits of the molecule nitric oxide. The company is developing BiDil, a nitric oxide-enhancing drug candidate, for the treatment of African Americans diagnosed with heart failure. BiDil has completed phase III confirmatory clinical trial. The company has collaboration agreement with Boston Scientific Corporation to jointly develop nitric oxide-enhanced paclitaxel-coated stents. NitroMed was founded by Joseph Loscalzo. The company was incorporated in 1992 and is based in Lexington, Massachusetts.
NEUROGEN CORPORATION (NRGN)
Neurogen Corporation engages in the discovery and development of small molecule drugs for neurological diseases, pain, inflammation, and metabolic diseases. The company, through its Accelerated Intelligent Drug Discovery platform, focuses on the development of drugs primarily relating to insomnia, pain, depression/anxiety, and obesity/diabetics. It lead proprietary drug candidate for insomnia includes NG2-73, a Phase I human testing product. The company has collaboration and license agreement with Merck Sharp & Dohme Limited for research, development, and commercialization of small molecule medicines, which work by targeting the vanilloid receptor, a key integrator of pain signals in the nervous system. The company also has collaborative research agreement with Pfizer, Inc. for the development of gamma-aminobutyric acid -based drugs for the treatment of sleep disorders. Neurogen was incorporated in 1987 and is based in Branford, Connecticut.
CORTEX PHARMACEUTICALS INC (COR)
Cortex Pharmaceuticals, Inc. engages in the discovery and development of pharmaceuticals for the treatment of neurological and psychiatric disorders. The company develops AMPAKINE drugs for the treatment of alzheimer's disease, mild cognitive impairment, schizophrenia, depression, narcolepsy, hyperactivity disorder, autism, fragile X, stroke, traumatic brain and spinal cord injury, parkinson's disease, and other neurological diseases. Its lead product includes AMPAKINE CX717, which has completed phase II clinical trial. The company has research collaboration agreements with N.V. Organon, which grants Organon rights to develop and commercialize the company's AMPAKINE technology for the treatment of schizophrenia and depression; and Les Laboratoires Servier that would allow Servier to develop and commercialize the company's AMPAKINE technology as a treatment for memory impairment associated with aging and neurodegenerative diseases. Cortex Pharmaceuticals was founded in 1987 and is based in Irvine, California.
CELL THERAPEUTICS INC (CTIC)
Cell Therapeutics, Inc. engages in the discovery, development, acquisition, and commercialization of drugs for the treatment of cancer. The company markets TRISENOX (arsenic trioxide) for the treatment of relapsed or refractory acute promyelocytic leukemia. Cell Therapeutics develops XYOTAX, paclitaxel linked to a polyglutamate polymer, which is used for the potential treatment of nonsmall cell lung cancer and ovarian cancer. It uses a biodegradable protein polymer to deliver the chemotherapy paclitaxel principally to tumor tissue. The company develops pixantrone, which is in clinical trials for the potential treatment of relapsed aggressive nonhodgkin's lymphoma. It operates primarily in the United States and Italy. The company was co-founded by James A. Bianco, Louis A. Bianco, and Jack W. Singer in 1991. Cell Therapeutics is headquartered in Seattle, Washington.
Pharmacyclics, Inc., a pharmaceutical company, develops products for the treatment of cancer, atherosclerosis, and other diseases. It offers Xcytrin, an anti-cancer agent designed to target cancer cells and, by disrupting cell metabolism, induce cell death through a cellular process, known as apoptosis. The company also develops Antrin angiophototherapy, which completed phase 1 clinical trails, for the treatment of atherosclerosis involving the coronary arteries of the heart. Pharmacyclics was co-founded by Richard A. Miller in 1991 and is headquartered in Sunnyvale, California.
Sepracor, Inc., a research-based pharmaceutical company, engages in the discovery, development, and commercialization of differentiated products primarily for the treatment of respiratory and central nervous system disorders. It commercializes two proprietary products, LUNESTA eszopiclone for the treatment of insomnia in patients who experience difficulty falling asleep, as well as for the treatment of patients who have difficulty sleeping through the night; and XOPENEX levalbuterol Inhalation Solution, a short-acting bronchodilator, for the treatment or prevention of bronchospasm in patients with reversible obstructive airway disease, such as asthma. Additionally, XOPENEX HFA (levalbuterol tartrate) Inhalation Aerosol, a hydrofluoroalkane (HFA) metered-dose inhaler is approved for the treatment or prevention of bronchospasm in adults, adolescents, and children four years of age and older with reversible obstructive airway disease. The company also has two drug candidates in Phase II and other drug compounds in earlier stages of development, including (S)-amlodipine for the treatment of hypertension; SEP-226330 for the treatment of restless legs syndrome; SEP-225289 for the treatment of depression; and SEP-227162 also for the treatment of depression. In addition, Sepracor has out-licensed the rights to various marketed drugs that include Schering-Plough's CLARINEX (desloratadine); sanofi-aventis's ALLEGRA (fexofenadine HCl); UCB Pharma's XYZAL/XUSAL (levocetirizine). Additionally, Sepracor has a research and development collaboration with ACADIA Pharmaceuticals to investigate potential clinical candidates targeted toward the treatment of central nervous system disorders. Sepracor was founded by Timothy J. Barberich in 1984 and is headquartered in Marlborough, Massachusetts.
LIGAND PHARMACEUTICALS INCORPORATED (LGND)
Ligand Pharmaceuticals Incorporated, a biotech company, engages in the discovery and development of drugs in the United States. It has research and development collaborations with pharmaceutical companies, including GlaxoSmithKline; Wyeth; Pfizer, Inc.; and TAP Pharmaceutical Products, Inc. for the treatment of market indications, such as thrombocytopenia, osteoporosis, menopausal symptoms, and frailty. The company's partnered products include Eltrombopag, a small-molecule TPO mimetic for thrombocytopenia, which is in phase III clinical trials; bazedoxifene, a monotherapy for osteoporosis; Aprela, a combination of bazedoxifene with PREMARIN for osteoporosis prevention, and vasomotor symptoms of menopause; and lasofoxifene, for osteoporosis and vaginal atrophy, which is in phase III clinical trials. Ligand Pharmaceuticals Incorporated was founded in 1987 and is headquartered in San Diego, California.
DUSA PHARMACEUTICALS INC (DUSA)
DUSA Pharmaceuticals, Inc., a pharmaceutical company, engages in the research, development, and marketing of a drug named 5-aminolevulinic acid (ALA). ALA is used in combination with appropriate light devices in order to detect or treat a variety of medical conditions, such as photodynamic therapy or photodetection. Its products include Levulan 20% topical solution using its Kerastick brand applicator, and BLU-U brand light unit for the treatment of actinic keratoses (AKs). AKs are precancerous skin lesions caused by chronic sun exposure that can develop over time into a form of skin cancer called squamous cell carcinoma. The company's products are used together to provide photodynamic therapy for the treatment of nonhyperkeratotic actinic keratoses of the face or scalp. Kerastick is a single-use, disposable applicator, which allows for the rapid preparation and uniform application of Levulan topical solution in standardized doses. In addition, the BLU-U is used without Levulan for the treatment of moderate inflammatory acne vulgaris and general dermatological conditions. The company offers its products through direct and third party distributors in the United States. DUSA Pharmaceuticals was incorporated in 1991 and is headquartered in Wilmington, Massachusetts.
Telik, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of small molecule drugs in the United States. Its primary product candidate, TELCYTA, is a small molecule tumor-activated cancer product candidate, which is being evaluated for the treatment of cancers that are resistant to standard chemotherapy drugs. The TELCYTA is in three Phase 3 registration trials for the treatment of advanced ovarian cancer, nonsmall cell lung cancer, and refractory ovarian cancer. The company's another product candidate, TELINTRA, is a small molecule bone marrow stimulant, which is being developed for the treatment of blood disorders associated with low blood cell levels, such as neutropenia or anemia. The TELINTRA is in Phase 2 trial in patients with myelodysplastic syndrome. Telik has collaboration agreements with Sanwa Kagaku Kenkyusho Co., Ltd. and Hoffmann-La Roche, Inc. The company was formed as Terrapin Diagnostics, Inc. in 1988 and changed its name to Terrapin Technologies, Inc. in 1989. Further, Terrapin Technologies changed its name to Telik, Inc. in 1998. Telik is based in Palo Alto, California.
KING PHARMACEUTICALS INC (KG)
King Pharmaceuticals, Inc. engages in the development, manufacture, marketing, and sale of branded prescription pharmaceutical products. It offers various branded prescription products over seven therapeutic areas, including cardiovascular, endocrinology, neuroscience, critical care, anti-infective, respiratory, and other. The company also develops, manufactures, and sells auto-injectors for the self-administration of injectable drugs. In addition, King Pharmaceuticals provides contract pharmaceutical manufacturing services to third-party pharmaceutical and biotechnology companies, as well as transfers company's manufacturing and marketing rights to third parties for licensing fees or royalty payments. The company distributes its branded pharmaceutical products primarily through wholesale pharmaceutical distributors and pharmacies to general/family practitioners, internal medicine physicians, cardiologists, endocrinologists, psychiatrists, neurologists, pain specialists, sleep specialists, and hospitals across the United States and in Puerto Rico. King Pharmaceuticals has a strategic collaboration relating to Intal (cromolyn sodium) and Tilade (nedocromil sodium), which includes the development of a new formulation of Intal utilizing hydrofluoroalkane, an environmentally friendly propellant; and with Pain Therapeutics, Inc. to develop and commercialize Remoxy and other abuse-resistant opioid painkillers. King Pharmaceuticals was incorporated in 1993 and is headquartered in Bristol, Tennessee.
Acusphere, Inc. operates as a specialty pharmaceutical company in the United States. It develops new drugs and improved formulations of existing drugs using its proprietary microparticle technology. The company has three product candidates in clinical development in the areas of cardiology, oncology, and asthma. Its primary product candidate, AI-700, a cardiovascular drug and an ultrasound contrast agent is in Phase III clinical development for the detection of coronary artery disease. Acusphere was co-founded by Robert S. Langer and Sherri C. Oberg in 1993. The company is headquartered in Watertown, Massachusetts.
Santarus, Inc., a specialty pharmaceutical company, engages in the acquisition, development, and commercialization of products for the prevention and treatment of gastrointestinal diseases and disorders. It offers ZEGERID Powder for Oral Suspension 20 mg, an immediate-release formulation of the proton pump inhibitor omeprazole. This product is approved by the U.S. Food and Drug Administration (FDA) for the treatment of heartburn and other symptoms associated with gastroesophageal reflux disease, treatment and maintenance of healing of erosive esophagitis, and treatment of duodenal ulcers. The company also offers ZEGERID Powder for Oral Suspension 40 mg, approved by the FDA for the treatment of gastric ulcers and the reduction of risk of upper gastrointestinal bleeding in critically ill patients. ZEGERID Powder for Oral Suspension is marketed in the U.S. by Santarus and its co-promotion partner, Otsuka America Pharmaceutical, Inc. In addition, Santarus is developing ZEGERID Chewable Tablets (40 mg and 20 mg) and ZEGERID Capsules for which it has submitted new drug applications. The company has strategic sublicense agreement with TAP Pharmaceutical Products, Inc. Santarus was formed in 1996 and was formerly known as TBG Pharmaceuticals, Inc. The company is headquartered in San Diego, California.
Neurochem, Inc., a biopharmaceutical company, engages in the development and commercialization of therapeutics for neurological disorders. The company's products portfolio include Fibrillex, a phase III clinical trial completed product for the treatment of AA Amyloidosis; Alzhemed, a phase III clinical trial product for the treatment of Alzheimer's diseases; Cerebril, a phase IIa clinical trial completed product for the prevention of hemorrhagic stroke caused by cerebral amyloid angiopathy; and NC-1461, which is in preclinical testing for the prevention of epileptic seizures. In addition to these clinical and developmental stage drug candidates, Neurochem has ongoing discovery programs that are focused on the development of compounds for the treatment of Alzheimer's disease (AD), and of a vaccine for AD, as well as researching various other aspects of neuroprotection and other amyloid-related disorders. Its vaccine program consists of a modified A (beta) peptide to induce an immune response. Further, the company has a minority investment in Innodia, Inc., which focuses on developing therapeutic treatments for diabetes. Neurochem was incorporated in 1993 and is headquartered in Laval, Canada.
AVANIR PHARMACEUTICALS (AVNR)
Avanir Pharmaceuticals, a pharmaceutical company, focuses on developing, acquiring, and commercializing therapeutic products for the treatment of chronic diseases. Its products and product candidates address therapeutic markets, including the central nervous system, inflammation, and infectious diseases. The company's lead product candidate Zenvia is being developed for the treatment of pseudobulbar affect (PBA), also known as involuntary emotional expression disorder. Zenvia also completed Phase III clinical trial in patients with diabetic peripheral neuropathic (DPN) pain. Avanir's infectious disease drug candidate, AVP-21D9 is a human monoclonal antibody that is in pre-clinical development for the treatment of anthrax. The company has also licensed a compound to Novartis International Pharmaceutical, Ltd. for the treatment of inflammatory disease. In addition, the company's commercialized product, Abreva is an over-the-counter product for the treatment of cold sores and is marketed in North America by GlaxoSmithKline Consumer Healthcare. Further, it is using its Xenerex technology to develop human monoclonal antibodies for use as prophylactic and therapeutic drugs to prevent and treat anthrax and other infectious diseases. The company was founded in 1988 and is headquartered in Aliso Viejo, California.
AtheroGenics, Inc. engages in the discovery, development, and commercialization of therapeutics for the treatment of chronic inflammatory diseases, including coronary heart disease, organ transplant rejection, rheumatoid arthritis, and asthma. It owns a proprietary vascular protectant technology (v-protectant) platform to discover drugs to treat these types of diseases. Based on this v-protectant platform, the company has two drug development programs. The company's AGI-1067 is a v-protectant candidate that is designed to benefit patients with coronary heart disease, which is atherosclerosis of the blood vessels of the heart. Its AGI-1067 is also being evaluated in the pivotal Phase III clinical trials called ARISE, as an oral therapy for the treatment of atherosclerosis. AtheroGenics' AGI-1096, a v-protectant candidate, is an antioxidant and selective anti-inflammatory agent for accelerated inflammation of grafted blood vessels. AGI-1096 inhibits the expression of certain inflammatory proteins, including VCAM-1, in endothelial cells lining the inside surfaces of blood vessel walls. In addition, AtheroGenics has preclinical programs in rheumatoid arthritis and asthma using its v-protectant platform. The company has collaboration agreement with Astellas Pharma. AtheroGenics was organized in 1993 and is headquartered in Alpharetta, Georgia.